Navigation Links
Carmen Marc Valvo, Designer and Cancer Survivor, Teams Up With Dulcolax® and the Colon Cancer Alliance to Make it Fashionable for Americans to Get Screened
Date:3/1/2011

RIDGEFIELD, Conn., March 1, 2011 /PRNewswire/ -- To kick off national Colon Cancer Awareness Month, the makers of Dulcolax® products and the Colon Cancer Alliance (CCA) have teamed up with American fashion designer, Carmen Marc Valvo, to fight the fears of the colonoscopy. Colon cancer is 90 percent curable when diagnosed early so why do so many Americans avoid getting a colonoscopy—the colon cancer screening test that could save their lives?

Men and women are recommended to begin screening at age 50, or even earlier if there is a family history of colon cancer. Despite these guidelines, alarming results from a new survey show that more than a quarter of respondents 50 years and older (27%) have not been screened, and the reason most often cited is that they do not have a family history of colon cancer. Moreover, of those aged 50 and older who have yet to be screened, 60 percent would be more concerned about the preparation than the actual procedure.

Fortunate to receive an early diagnosis after being screened for the disease, it has been eight years since Valvo has beaten colon cancer. "I certainly understand why people are hesitant to be examined, but the fact is, it's not nearly as uncomfortable as you might imagine, and any discomfort from the screening is surely outweighed by the benefits of preventing cancer from developing or catching it in its early stages," says Valvo.

In 2003, Valvo knew something was not right and insisted to his doctors that he be screened. Doctors found a growth in his colon, but Valvo was able to have it removed and survived the disease. He has since committed himself to advocating for screening and supporting colon cancer research.

"A colonoscopy is now considered a routine test that has saved countless lives over the years," said Michael Kreines, MD, FACG, FAGA, FACP, Ohio Gastroenterology and Liver Institute, member of the Colon Cancer Alliance Medical Scientific Advisory Board. "In addition to regular screening, you can reduce your risk of colon cancer by maintaining a healthy diet and staying active.  Take action and discuss having a colonoscopy with your doctor, who can tell you exactly what to expect and help calm your fears."

Valvo continued, "I wasn't aware I had a family history of colon cancer, and my triumph over the disease has empowered me to make sure people are aware of what they can do to prevent and fight it. Fear and embarrassment often make people reluctant to undergo the screening process, but I can't stress how important it is to keep testing. When it comes to combating this disease, early detection and treatment are the keys."  

The makers of Dulcolax® products are a proud supporter of the Colon Cancer Alliance. A portion of proceeds from the purchase of Dulcolax® supports free colon cancer screenings for those in need. As the #1 doctor recommended stimulant for constipation relief, Dulcolax® reminds everyone over the age of 50 or with a family history of colon cancer, that a colonoscopy can save lives. Talk to your doctor to get screened.

About Dulcolax®Dulcolax® products of Boehringer Ingelheim Pharmaceuticals, Inc., have been a leader in constipation relief for over 50 years. Dulcolax® offers a range of solutions for relief from constipation, including Dulcolax® Laxative Tablets, Dulcolax® Laxative Suppositories, Dulcolax® Stool Softeners and Dulcolax Balance®. A portion of the proceeds from every Dulcolax® purchase supports free colon cancer screenings for those in need. For more information on the #1 doctor recommended stimulant for constipation relief, visit www.dulcolaxusa.com.

About the Colon Cancer Alliance The Colon Cancer Alliance (CCA) is a national patient advocacy organization dedicated to ending the suffering caused by colorectal cancer. In order to increase rates of screening and survivorship, the Colon Cancer Alliance provides patient support and public education, supports research and conducts advocacy work across America. For more information, please visit www.ccalliance.org.

About the SurveyOn behalf of Boehringer Ingelheim Pharmaceuticals, Inc. and the Colon Cancer Alliance, Kelton Research conducted the survey in the U.S. online during February 2011. One thousand nationally representative American men and women were surveyed, all of whom were 18 years of age and older. This survey was made possible through funding provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results.  In this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.  Margins of error for specific subgroups are higher.

About Carmen Marc ValvoAmerican fashion designer Carmen Marc Valvo is the top-selling eveningwear designer at Neiman Marcus, and his lines have expanded to include eyewear, lingerie, a swimsuit line and a home collection. Valvo is a colorectal cancer survivor and has been very active in championing the cause. He serves as an Entertainment Industry Foundation (EIF) ambassador and has partnered with the EIF's National Colorectal Cancer Research Alliance (NCCRA), which is dedicated to the eradication of colorectal cancer by promoting the importance of early medical screening and funding research to develop better tests, treatments, and ultimately a cure. Valvo's latest fashion book, Dressed to Perfection: The Art of Dressing for Your Red Carpet Moments, was published last month, and proceeds from sales of the book will go to colon cancer organizations. For more information, visit www.carmenmarcvalvo.com.About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

*On behalf of Boehringer Ingelheim Pharmaceuticals, Inc. and the Colon Cancer Alliance, Kelton Research conducted the survey in the U.S. online during February 2011. One thousand nationally representative American men and women were surveyed, all of whom were 18 years of age and older. This survey was made possible through funding provided by Boehringer Ingelheim Pharmaceuticals, Inc.Media Contact:Susan HolzPublic Affairs & CommunicationsBoehringer Ingelheim Pharmaceuticals, Inc.Phone: 203-798-4265Email: usnews@boehringer-ingelheim.com
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UBM Electronics EE Times and EDN Partner with Medical Electronics Design, MD+DI, and Others on DesignMED Event for Designers of Medical Electronics Devices
2. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
3. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
4. The Smilow Comprehensive Prostate Cancer Center Installs Eigen ei-Nav
5. Artemis™
6. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
7. Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
8. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
9. High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology
10. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
11. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):